gabapentin has been researched along with Chemical Dependence in 67 studies
Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Gabapentin is a relatively new anticonvulsant being investigated for potential use in the treatment of bipolar disorder (BD), anxiety disorders, behavioral dyscontrol, and substance use disorders." | 8.80 | Gabapentin: a review of published experience in the treatment of bipolar disorder and other psychiatric conditions. ( Letterman, L; Markowitz, JS, 1999) |
| "Gabapentin (Neurontin) is approved by the US Food and Drug Administration for treatment of epilepsy and post-herpetic neuralgia." | 7.75 | Gabapentin-induced delirium and dependence. ( Kahn, DA; Kruszewski, SP; Paczynski, RP, 2009) |
| "Epilepsy is a common condition in people with learning disabilities with many patients continuing to suffer from seizures despite antiepileptic drug (AED) treatment." | 5.30 | A naturalistic study of the use of vigabatrin, lamotrigine and gabapentin in adults with learning disabilities. ( Bhaumik, S; Branford, D; Duggirala, C; Ismail, IA, 1997) |
| "gov, and US FDA data, indexed through 28 July 2016, utilizing the following searches: pregabalin OR gabapentin OR gabapentinoid AND one of the following: abuse, misuse, overdose, or substance-related disorders[MESH], was conducted." | 4.95 | Abuse and Misuse of Pregabalin and Gabapentin. ( Evoy, KE; Morrison, MD; Saklad, SR, 2017) |
| " Gabapentin is a relatively new anticonvulsant being investigated for potential use in the treatment of bipolar disorder (BD), anxiety disorders, behavioral dyscontrol, and substance use disorders." | 4.80 | Gabapentin: a review of published experience in the treatment of bipolar disorder and other psychiatric conditions. ( Letterman, L; Markowitz, JS, 1999) |
| "Gabapentinoid use for long-term cancer pain control may be problematic, given unclear mechanisms of action and increased concerns for physical dependence." | 3.96 | Use of gabapentinoid medications among US adults with cancer, 2005-2015. ( Choi, SW; Davis, MA; Fauer, AJ; Friese, CR; Wallner, LP, 2020) |
| "Gabapentin, a prescription medication approved for the treatment of seizures and neuralgia, is often prescribed off-label for substance use treatment, mental health problems, and pain." | 3.91 | Gabapentin prescribed during substance abuse treatment: The perspective of treatment providers. ( Buttram, ME; Cicero, TJ; Ellis, MS; Kurtz, SP, 2019) |
| "Gabapentin (Neurontin) is approved by the US Food and Drug Administration for treatment of epilepsy and post-herpetic neuralgia." | 3.75 | Gabapentin-induced delirium and dependence. ( Kahn, DA; Kruszewski, SP; Paczynski, RP, 2009) |
| "The epidemics of chronic pain and opioid misuse have given rise to the widespread use of non-opioid drugs such as the gabapentinoids for treatment." | 2.72 | The gabapentinoid drugs and their abuse potential. ( Alles, SRA; Goins, A; Patel, K, 2021) |
| " Given its faster onset, increased bioavailability and potency, and nonsaturable absorption, pregabalin's pharmacokinetics theoretically enhance its misuse liability versus gabapentin." | 2.72 | Gabapentinoid Pharmacology in the Context of Emerging Misuse Liability. ( Covvey, JR; Evoy, KE; Peckham, AM; Tidgewell, KJ, 2021) |
| "Gabapentin is an important adjuvant to the management of opiate dependence both in acute detoxification as well as stabilisation phase." | 2.71 | Gabapentin in the management of pentazocine dependence: a potent analgesic--anticraving agent. ( Jain, MK; Kumar, P, 2003) |
| "Both gabapentinoids were anxiolytic in therapeutic doses, stimulating in lower and sedating along with increasing doses." | 2.58 | [On the risk of dependence on gabapentinoids]. ( Bonnet, U; Scherbaum, N, 2018) |
| "A history of alcohol or substance abuse appears to be an important part of a patient's medical history when evaluating their risk for addiction and dependence behaviors." | 2.53 | Gabapentin: Abuse, Dependence, and Withdrawal. ( Mersfelder, TL; Nichols, WH, 2016) |
| "Gabapentin was misused primarily for recreational purposes, self-medication or intentional self-harm and was misused alone or in combination with other substances, especially opioids, benzodiazepines and/or alcohol." | 2.53 | Gabapentin misuse, abuse and diversion: a systematic review. ( Havens, JR; Smith, RV; Walsh, SL, 2016) |
| " Overall, pregabalin is characterized by higher potency, quicker absorption rates and greater bioavailability levels than gabapentin." | 2.50 | Misuse and abuse of pregabalin and gabapentin: cause for concern? ( Schifano, F, 2014) |
| "Chronic pain is now viewed as a biopsychosocial phenomenon, in which biological, psychological, and social factors are at work." | 2.44 | Practical management strategies for the chronic pain patient. ( Forde, G; Stanos, S, 2007) |
| "Gabapentinoid misuse was commonly framed in comparative fashion to ongoing concerns with opioids, and proposed solutions often focused less on regulatory control and more toward patient and HCP education and an overhaul of the health system approach to substance use and healthcare overall." | 1.91 | Pharmacist, prescriber, and drug policy expert opinions on gabapentinoid misuse. ( Blakely, ML; Covvey, JR; Evoy, KE; Peckham, AM; Singh, R, 2023) |
| "The gabapentinoids were reclassified as Schedule II medications and Class C drugs in the UK in 2019 due to their potential misuse." | 1.72 | Fatalities associated with gabapentinoids in England (2004-2020). ( Baho, H; Chiu, CT; Copeland, CS; Kalk, NJ; Sadoughi, R; Taylor, D; Williams, BD, 2022) |
| "Baclofen (BLF) has been prescribed in the UK since 1972 for the alleviation of spasticity." | 1.62 | Baclofen: To Screen or Not to Screen in Postmortem Blood? ( Murphy, KG; Nahar, LK; Paterson, S, 2021) |
| "Using FDA Adverse Events Reporting System reports from January 1, 2005 to December 31, 2015, we calculated pharmacovigilance signal measures (i." | 1.56 | Gabapentin drug misuse signals: A pharmacovigilance assessment using the FDA adverse event reporting system. ( Charnigo, RJ; Havens, JR; Lofwall, MR; Sun, J; Vickers-Smith, R; Walsh, SL, 2020) |
| "Gabapentin (GBP) was identified in 118 samples (13%) and pregabalin (PRG) in 32 samples (3." | 1.56 | An Insight into Gabapentin and Pregabalin in Scottish Prisoners. ( Deeb, S; Scott, KS; Torrance, HJ; Wylie, FM, 2020) |
| "Substance use is prevalent in Canada, yet treatment is inaccessible." | 1.56 | A rapid access to addiction medicine clinic facilitates treatment of substance use disorder and reduces substance use. ( Hulme, J; Sheikh, H; Wiercigroch, D, 2020) |
| "Gabapentin is an anticonvulsant medication with an indication from the US Food and Drug Administration for use in partial onset seizures and postherpetic neuralgia in the United States." | 1.51 | A Call for Caution in Prescribing Gabapentin to Individuals With Concurrent Polysubstance Abuse: A Case Report. ( Hasan, S; Martinez, GM; Olabisi, J; Ruekert, L, 2019) |
| " Pharmacovigilance data from the Food and Drug Administration Adverse Event Reporting System (FAERS) provides a useful examination of adverse drug event (ADE) reporting for safety signal detection." | 1.51 | Reports of gabapentin and pregabalin abuse, misuse, dependence, or overdose: An analysis of the Food And Drug Administration Adverse Events Reporting System (FAERS). ( Covvey, JR; Evoy, KE; Hultgren, KE; Ochs, L; Peckham, AM, 2019) |
| "Gabapentin misuse has been associated with drug-related harm and increased healthcare service utilization in a few studies, including a recent large-sample analysis of commercially insured enrollees in the United States (U." | 1.48 | Policies to mitigate nonmedical use of prescription medications: how should emerging evidence of gabapentin misuse be addressed? ( Fairman, KA; Peckham, AM; Sclar, DA, 2018) |
| "All patients had substance use disorders, the large majority (72 %) to more than one substance." | 1.43 | Abuse of Gabapentin is Associated with Opioid Addiction. ( Bastiaens, L; Galus, J; Mazur, C, 2016) |
| "Drug abuse was associated with 48." | 1.40 | Profiles of pregabalin and gabapentin abuse by postmortem toxicology. ( Gergov, M; Häkkinen, M; Kalso, E; Ojanperä, I; Vuori, E, 2014) |
| "Some patients had no known history of substance abuse." | 1.38 | Gabapentin and pregabalin: abuse and addiction. ( , 2012) |
| "Epilepsy is a common condition in people with learning disabilities with many patients continuing to suffer from seizures despite antiepileptic drug (AED) treatment." | 1.30 | A naturalistic study of the use of vigabatrin, lamotrigine and gabapentin in adults with learning disabilities. ( Bhaumik, S; Branford, D; Duggirala, C; Ismail, IA, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (4.48) | 18.2507 |
| 2000's | 9 (13.43) | 29.6817 |
| 2010's | 38 (56.72) | 24.3611 |
| 2020's | 17 (25.37) | 2.80 |
| Authors | Studies |
|---|---|
| Zhao, D | 1 |
| Nunes, AP | 1 |
| Baek, J | 1 |
| Lapane, KL | 1 |
| Kalk, NJ | 1 |
| Chiu, CT | 1 |
| Sadoughi, R | 1 |
| Baho, H | 1 |
| Williams, BD | 1 |
| Taylor, D | 1 |
| Copeland, CS | 1 |
| Laribi, M | 1 |
| Chaouali, N | 1 |
| Jaballah, S | 1 |
| Amira, D | 1 |
| Hedhili, A | 1 |
| Covvey, JR | 5 |
| Blakely, ML | 2 |
| Singh, R | 2 |
| Peckham, AM | 8 |
| Evoy, KE | 6 |
| Akbar, MF | 1 |
| Ikram, A | 1 |
| Naeem, A | 1 |
| Reinert, JP | 1 |
| Dunn, RL | 1 |
| Buttram, ME | 3 |
| Kurtz, SP | 3 |
| Ellis, MS | 1 |
| Cicero, TJ | 1 |
| Marsden, J | 1 |
| White, M | 1 |
| Annand, F | 1 |
| Burkinshaw, P | 1 |
| Carville, S | 1 |
| Eastwood, B | 1 |
| Kelleher, M | 1 |
| Knight, J | 1 |
| O'Connor, R | 1 |
| Tran, A | 1 |
| Willey, P | 1 |
| Greaves, F | 1 |
| Taylor, S | 1 |
| Fauer, AJ | 1 |
| Davis, MA | 1 |
| Choi, SW | 1 |
| Wallner, LP | 1 |
| Friese, CR | 1 |
| Vickers-Smith, R | 1 |
| Sun, J | 1 |
| Charnigo, RJ | 1 |
| Lofwall, MR | 2 |
| Walsh, SL | 2 |
| Havens, JR | 3 |
| Deeb, S | 1 |
| Wylie, FM | 1 |
| Torrance, HJ | 1 |
| Scott, KS | 1 |
| Wiercigroch, D | 1 |
| Sheikh, H | 1 |
| Hulme, J | 1 |
| Hägg, S | 1 |
| Jönsson, AK | 1 |
| Ahlner, J | 1 |
| Nahar, LK | 2 |
| Murphy, KG | 2 |
| Paterson, S | 2 |
| Peltokorpi, J | 1 |
| Hakko, H | 1 |
| Riipinen, P | 1 |
| Riala, K | 1 |
| Sadrameli, S | 1 |
| Contreras, J | 1 |
| Goins, A | 1 |
| Patel, K | 1 |
| Alles, SRA | 1 |
| Tidgewell, KJ | 1 |
| Wee, TC | 1 |
| Fairman, KA | 2 |
| Sclar, DA | 3 |
| Dart, RC | 1 |
| Margolin, ZR | 1 |
| Heeren, N | 1 |
| Farver, D | 1 |
| Bonnet, U | 3 |
| Scherbaum, N | 4 |
| Throckmorton, DC | 1 |
| Gottlieb, S | 1 |
| Woodcock, J | 1 |
| Richter, EL | 1 |
| Isbruch, K | 1 |
| Tomko, JR | 1 |
| Prasad, KM | 1 |
| Kubas, S | 1 |
| Simpson, T | 1 |
| Lauhan, R | 1 |
| Hsu, A | 1 |
| Alam, A | 1 |
| Beizai, K | 1 |
| Tharp, AM | 1 |
| Hobron, K | 1 |
| Wright, T | 1 |
| Driot, D | 1 |
| Jouanjus, E | 1 |
| Oustric, S | 1 |
| Dupouy, J | 1 |
| Lapeyre-Mestre, M | 1 |
| Martinez, GM | 1 |
| Olabisi, J | 1 |
| Ruekert, L | 1 |
| Hasan, S | 1 |
| Ochs, L | 1 |
| Hultgren, KE | 1 |
| Paino, M | 1 |
| Aletraris, L | 1 |
| Roman, PM | 1 |
| Rohman, L | 1 |
| Hebron, A | 1 |
| Baird, CR | 1 |
| Fox, P | 1 |
| Colvin, LA | 1 |
| Howland, RH | 2 |
| Schifano, F | 3 |
| Häkkinen, M | 1 |
| Vuori, E | 1 |
| Kalso, E | 1 |
| Gergov, M | 1 |
| Ojanperä, I | 1 |
| Smith, RV | 2 |
| Mersfelder, TL | 1 |
| Nichols, WH | 1 |
| Bastiaens, L | 1 |
| Galus, J | 1 |
| Mazur, C | 1 |
| Mariani, JJ | 1 |
| Malcolm, RJ | 1 |
| Mamczur, AK | 1 |
| Choi, JC | 1 |
| Brady, R | 1 |
| Nunes, E | 1 |
| Levin, FR | 1 |
| Chiappini, S | 1 |
| Stannard, C | 1 |
| Morrison, MD | 1 |
| Saklad, SR | 1 |
| Forde, G | 1 |
| Stanos, S | 1 |
| Apgar, BS | 1 |
| Mondón, S | 1 |
| Nogué, S | 1 |
| Urbano, D | 1 |
| Rovira, E | 1 |
| Kruszewski, SP | 1 |
| Paczynski, RP | 1 |
| Kahn, DA | 1 |
| Kurokawa, K | 1 |
| Shibasaki, M | 1 |
| Mizuno, K | 1 |
| Ohkuma, S | 1 |
| D'Offizi, S | 1 |
| Piccione, M | 1 |
| Corazza, O | 1 |
| Deluca, P | 1 |
| Davey, Z | 1 |
| Di Melchiorre, G | 1 |
| Di Furia, L | 1 |
| Farré, M | 1 |
| Flesland, L | 1 |
| Mannonen, M | 1 |
| Majava, A | 1 |
| Pagani, S | 1 |
| Peltoniemi, T | 1 |
| Siemann, H | 1 |
| Skutle, A | 1 |
| Torrens, M | 1 |
| Pezzolesi, C | 1 |
| van der Kreeft, P | 1 |
| Voris, J | 1 |
| Smith, NL | 1 |
| Rao, SM | 1 |
| Thorne, DL | 1 |
| Flowers, QJ | 1 |
| Kumar, P | 1 |
| Jain, MK | 1 |
| Heinzerling, KG | 1 |
| Shoptaw, S | 1 |
| Peck, JA | 1 |
| Yang, X | 1 |
| Liu, J | 1 |
| Roll, J | 1 |
| Ling, W | 1 |
| Victorri-Vigneau, C | 1 |
| Guerlais, M | 1 |
| Jolliet, P | 1 |
| Urschel, HC | 1 |
| Hanselka, LL | 1 |
| Gromov, I | 1 |
| White, L | 1 |
| Baron, M | 1 |
| Bhaumik, S | 1 |
| Branford, D | 1 |
| Duggirala, C | 1 |
| Ismail, IA | 1 |
| Markowitz, JS | 2 |
| Finkenbine, R | 1 |
| Myrick, H | 1 |
| King, L | 1 |
| Carson, WH | 1 |
| Letterman, L | 1 |
| Crockford, D | 1 |
| White, WD | 1 |
| Campbell, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pragmatic, Multi-centre, Open-label, Randomized, 12-month, Parallel Group, Superiority Study to Compare the Effectiveness of Subcutaneous Buprenorphine Depot (Sublocade®) vs Daily Sublingual Buprenorphine With Naloxone (Suboxone®) for the Treatment of O[NCT05594121] | Phase 4 | 90 participants (Anticipated) | Interventional | 2022-12-31 | Not yet recruiting | ||
| Pattern of Acute Antipsychotic Drug- Toxicity in Children at Assiut University Children Hospital[NCT06125275] | 50 participants (Anticipated) | Observational | 2023-10-30 | Not yet recruiting | |||
| Erenumab as a Therapeutic Approach for the Management of Painful Chronic Temporomandibular Disorders (TMD)[NCT05162027] | Phase 2 | 5 participants (Actual) | Interventional | 2022-04-01 | Terminated (stopped due to Low enrollment rate) | ||
| Efficacy of Gabapentin for Post-Covid-19 Olfactory Dysfunction[NCT05184192] | Phase 2 | 50 participants (Anticipated) | Interventional | 2022-01-10 | Enrolling by invitation | ||
| A Randomized Controlled Pilot Trial of Gabapentin for the Treatment of Benzodiazepine Abuse in Methadone Maintenance Patients[NCT00420771] | Phase 2 | 19 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| Gabapentin Regimens and Their Effects on Opioid Consumption[NCT03334903] | Phase 4 | 77 participants (Actual) | Interventional | 2018-05-15 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Comparing the mean reduction change in Benzodiazepine use per day when comparing the baseline week prior to study entry to the last week of study participation based on the Time Line Follow Back (NCT00420771)
Timeframe: data collected during 8 weeks of trial or length of participation
| Intervention | milligrams/day (Mean) |
|---|---|
| Active Medication | 4.0 |
| Placebo | 2.3 |
Surgical site pain. Scale 0-10, with 0 best and 10 worst (NCT03334903)
Timeframe: 2-3 months after surgery (at 2nd postoperative appointment)
| Intervention | score on 10-point scale (Mean) |
|---|---|
| Standard of Care | 2.26 |
| Postoperative Gabapentin Regimen | 2.46 |
Surgical site pain. Scale 0-10, with 0 best and 10 worst. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).
| Intervention | score on a 10-point scale (Mean) |
|---|---|
| Standard of Care | 3.84 |
| Postoperative Gabapentin Regimen | 3.54 |
Sleep quality. Scale 0-10 with 0 worst and 10 best. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).
| Intervention | score on a 10-point scale (Mean) |
|---|---|
| Standard of Care | 5.73 |
| Postoperative Gabapentin Regimen | 6.38 |
Nausea. Scale 0-10, with 0 best and 10 worst. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).
| Intervention | score on a 10-point scale (Mean) |
|---|---|
| Standard of Care | 0.36 |
| Postoperative Gabapentin Regimen | 0.17 |
Satisfaction. Scale 0-10 with 0 worst and 10 best. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).
| Intervention | score on a 10-point scale (Mean) |
|---|---|
| Standard of Care | 7.83 |
| Postoperative Gabapentin Regimen | 8.48 |
Number of days until patients are finished consuming opioid medications after discharge. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).
| Intervention | days (Mean) |
|---|---|
| Standard of Care | 14.8 |
| Postoperative Gabapentin Regimen | 18.7 |
Mean opioid consumption, measured in mg of morphine equivalents. (NCT03334903)
Timeframe: 2-3 months following surgery (total amount measured at second postoperative appointment; means assessed afterwards).
| Intervention | morphine equivalents (Mean) |
|---|---|
| Standard of Care | 287.0 |
| Postoperative Gabapentin Regimen | 281.1 |
17 reviews available for gabapentin and Chemical Dependence
| Article | Year |
|---|---|
[Drug abuse of pregabalin - state of the situation, risks and means of control].
Topics: Anticonvulsants; Drug Overdose; Gabapentin; Humans; Pregabalin; Substance-Related Disorders | 2023 |
Management of overdoses of loperamide, gabapentin, and modafinil: a literature review.
Topics: Drug Overdose; Emergency Treatment; Gabapentin; Humans; Loperamide; Modafinil; Substance-Related Dis | 2019 |
Medicines associated with dependence or withdrawal: a mixed-methods public health review and national database study in England.
Topics: Acetamides; Adolescent; Adult; Aged; Analgesics; Analgesics, Opioid; Antidepressive Agents; Azabicyc | 2019 |
Current Evidence on Abuse and Misuse of Gabapentinoids.
Topics: Gabapentin; Humans; Pharmacovigilance; Prescription Drug Misuse; Risk Factors; Substance-Related Dis | 2020 |
The gabapentinoid drugs and their abuse potential.
Topics: Analgesics; Chronic Pain; Gabapentin; Humans; Pregabalin; Substance-Related Disorders | 2021 |
Gabapentinoid Pharmacology in the Context of Emerging Misuse Liability.
Topics: Area Under Curve; Calcium Channel Blockers; Drug Overdose; Gabapentin; Half-Life; Humans; Metabolic | 2021 |
How addictive are gabapentin and pregabalin? A systematic review.
Topics: Amines; Analgesics; Behavior, Addictive; Cyclohexanecarboxylic Acids; Databases, Bibliographic; Drug | 2017 |
[On the risk of dependence on gabapentinoids].
Topics: Analgesics; Behavior, Addictive; Gabapentin; Germany; Humans; Pregabalin; Risk; Substance-Related Di | 2018 |
On the addictive power of gabapentinoids: a mini-review.
Topics: Adult; Amines; Animals; Comorbidity; Craving; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobu | 2018 |
Tianeptine Abuse and Dependence: Case Report and Literature Review.
Topics: Adult; Aged; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Diazepam; Female; Gabapentin; Hu | 2018 |
Gabapentin for the treatment of substance use disorders.
Topics: Amines; Antimanic Agents; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; | 2013 |
Misuse and abuse of pregabalin and gabapentin: cause for concern?
Topics: Amines; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Pregabalin; Prescr | 2014 |
Gabapentin: Abuse, Dependence, and Withdrawal.
Topics: Amines; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Substance Abuse Tr | 2016 |
Gabapentin: Abuse, Dependence, and Withdrawal.
Topics: Amines; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Substance Abuse Tr | 2016 |
Gabapentin: Abuse, Dependence, and Withdrawal.
Topics: Amines; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Substance Abuse Tr | 2016 |
Gabapentin: Abuse, Dependence, and Withdrawal.
Topics: Amines; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Substance Abuse Tr | 2016 |
Gabapentin misuse, abuse and diversion: a systematic review.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Prescr | 2016 |
Abuse and Misuse of Pregabalin and Gabapentin.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Overdose; Gabapentin; gamma-Aminobutyric Acid; | 2017 |
Practical management strategies for the chronic pain patient.
Topics: Administration, Cutaneous; Amines; Analgesics; Antidepressive Agents, Tricyclic; Carbamazepine; Chro | 2007 |
Gabapentin: a review of published experience in the treatment of bipolar disorder and other psychiatric conditions.
Topics: Acetates; Amines; Anticonvulsants; Anxiety; Bipolar Disorder; Cyclohexanecarboxylic Acids; Gabapenti | 1999 |
3 trials available for gabapentin and Chemical Dependence
| Article | Year |
|---|---|
Pilot trial of gabapentin for the treatment of benzodiazepine abuse or dependence in methadone maintenance patients.
Topics: Adolescent; Adult; Aged; Amines; Benzodiazepines; Combined Modality Therapy; Cyclohexanecarboxylic A | 2016 |
Gabapentin in the management of pentazocine dependence: a potent analgesic--anticraving agent.
Topics: Acetates; Amines; Analgesics; Analgesics, Opioid; Anti-Anxiety Agents; Clonidine; Cyclohexanecarboxy | 2003 |
Randomized, placebo-controlled trial of baclofen and gabapentin for the treatment of methamphetamine dependence.
Topics: Adult; Amines; Anti-Anxiety Agents; Baclofen; Central Nervous System Stimulants; Cyclohexanecarboxyl | 2006 |
47 other studies available for gabapentin and Chemical Dependence
| Article | Year |
|---|---|
An algorithm to identify gabapentin misuse and/or abuse in administrative claims data.
Topics: Algorithms; Analgesics, Opioid; Gabapentin; Humans; Male; Odds Ratio; Prescription Drug Misuse; Subs | 2022 |
Fatalities associated with gabapentinoids in England (2004-2020).
Topics: Analgesics, Opioid; England; Gabapentin; Humans; Pregabalin; Substance-Related Disorders | 2022 |
Pharmacist, prescriber, and drug policy expert opinions on gabapentinoid misuse.
Topics: Expert Testimony; Gabapentin; Humans; Pharmacists; Policy; Substance-Related Disorders | 2023 |
Pharmacist, prescriber, and drug policy expert opinions on gabapentinoid misuse.
Topics: Expert Testimony; Gabapentin; Humans; Pharmacists; Policy; Substance-Related Disorders | 2023 |
Pharmacist, prescriber, and drug policy expert opinions on gabapentinoid misuse.
Topics: Expert Testimony; Gabapentin; Humans; Pharmacists; Policy; Substance-Related Disorders | 2023 |
Pharmacist, prescriber, and drug policy expert opinions on gabapentinoid misuse.
Topics: Expert Testimony; Gabapentin; Humans; Pharmacists; Policy; Substance-Related Disorders | 2023 |
Increasing Trends in Abuse of Gabapentin in Drug Addicts in Rural Population of Punjab.
Topics: Drug Users; Gabapentin; Humans; Rural Population; Substance-Related Disorders | 2023 |
Gabapentin prescribed during substance abuse treatment: The perspective of treatment providers.
Topics: Analgesics; Florida; Gabapentin; Health Personnel; Humans; Interviews as Topic; Off-Label Use; Pain; | 2019 |
Use of gabapentinoid medications among US adults with cancer, 2005-2015.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analgesics; Cancer Pain; Chronic Pain; Cross-Sectional S | 2020 |
Gabapentin drug misuse signals: A pharmacovigilance assessment using the FDA adverse event reporting system.
Topics: Adverse Drug Reaction Reporting Systems; Bayes Theorem; Databases, Factual; Duloxetine Hydrochloride | 2020 |
An Insight into Gabapentin and Pregabalin in Scottish Prisoners.
Topics: Female; Gabapentin; Humans; Male; Pregabalin; Prisoners; Scotland; Substance Abuse Detection; Substa | 2020 |
A rapid access to addiction medicine clinic facilitates treatment of substance use disorder and reduces substance use.
Topics: Acamprosate; Addiction Medicine; Adult; Aged; Alcohol Deterrents; Alcoholism; Buprenorphine; Emergen | 2020 |
Baclofen: To Screen or Not to Screen in Postmortem Blood?
Topics: Autopsy; Baclofen; Gabapentin; Humans; Pregabalin; Substance-Related Disorders | 2021 |
A Qualitative Examination of Gabapentin Misuse Inside of Treatment and Recovery Settings.
Topics: Adult; Analgesics, Opioid; Female; Gabapentin; Humans; Male; Middle Aged; Prescription Drug Misuse; | 2020 |
Profile of Substance Misuse among Adolescent and Young Adult Gabapentinoid Users: A Register-Based Follow-up Study of Former Adolescent Psychiatric Inpatients.
Topics: Adolescent; Female; Finland; Follow-Up Studies; Gabapentin; Humans; Inpatients; Male; Substance-Rela | 2021 |
Authors' Reply to Bonnet et al. "Abuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update".
Topics: Amines; Gabapentin; Humans; Pregabalin; Substance-Related Disorders | 2021 |
The Potential for Gabapentinoid Abuse in Pain Management.
Topics: Analgesics; Gabapentin; Humans; Neuralgia; Pain Management; Pregabalin; Substance-Related Disorders | 2017 |
Prevalence of Gabapentin Abuse: Comparison with Agents with Known Abuse Potential in a Commercially Insured US Population.
Topics: Adolescent; Adult; Amines; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid; | 2017 |
Law enforcement-derived data on gabapentin diversion and misuse, 2002-2015: diversion rates and qualitative research findings.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Data Collection; Female; Gabapentin; gamma-Aminobut | 2017 |
You Abused What? Getting High with Unique Medications.
Topics: Amines; Anticonvulsants; Antidiarrheals; Antipsychotic Agents; Antitussive Agents; Cyclohexanecarbox | 2017 |
Policies to mitigate nonmedical use of prescription medications: how should emerging evidence of gabapentin misuse be addressed?
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug and Narcotic Control; Gabapentin; gamma-Aminob | 2018 |
The FDA and the Next Wave of Drug Abuse - Proactive Pharmacovigilance.
Topics: Amines; Analgesics, Opioid; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Drug Utilization | 2018 |
The Association of Gabapentin Use and Dose With Substance Use Disorders Prior to Inpatient Mental Health Treatment: A Cross-Sectional Study.
Topics: Adult; Amines; Cross-Sectional Studies; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Dru | 2018 |
Gabapentin-related Deaths: Patterns of Abuse and Postmortem Levels.
Topics: Accidents; Chromatography, Liquid; Driving Under the Influence; Drug Overdose; Female; Gabapentin; H | 2019 |
Patterns of gabapentin and pregabalin use and misuse: Results of a population-based cohort study in France.
Topics: Adult; Aged; Drug Prescriptions; Drug Utilization; Female; France; Gabapentin; Humans; Incidence; Ma | 2019 |
Quantifying Gabapentin Misuse With Opioids.
Topics: Analgesics, Opioid; Cross-Sectional Studies; Gabapentin; Humans; Inpatients; Mental Health; Substanc | 2019 |
Misuse and Mortality Related to Gabapentin and Pregabalin are Being Under-Estimated: A Two-Year Post-Mortem Population Study.
Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; England; Female; Forensic Toxicology; Gabapentin; He | 2019 |
A Call for Caution in Prescribing Gabapentin to Individuals With Concurrent Polysubstance Abuse: A Case Report.
Topics: Adult; Anticonvulsants; Epilepsy; Female; Gabapentin; Humans; Substance-Related Disorders | 2019 |
Reports of gabapentin and pregabalin abuse, misuse, dependence, or overdose: An analysis of the Food And Drug Administration Adverse Events Reporting System (FAERS).
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Analgesics; Anticonvulsants; Databases, Factua | 2019 |
The use of off-label medications in substance abuse treatment programs.
Topics: Accreditation; Adrenergic alpha-2 Receptor Agonists; Anticonvulsants; Antiemetics; Baclofen; Clonidi | 2020 |
Acute dystonic reaction caused by gabapentin.
Topics: Acute Disease; Adult; Amines; Anti-Anxiety Agents; Cyclohexanecarboxylic Acids; Dystonia; Gabapentin | 2014 |
Gabapentinoid abuse in order to potentiate the effect of methadone: a survey among substance misusers.
Topics: Amines; Behavior, Addictive; Cyclohexanecarboxylic Acids; Data Collection; Drug Synergism; Gabapenti | 2014 |
Gabapentin: can it be misused?
Topics: Amines; Controlled Substances; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric A | 2014 |
Profiles of pregabalin and gabapentin abuse by postmortem toxicology.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amines; Anticonvulsants; Chromatography, Liquid; Cyclohe | 2014 |
Abuse and diversion of gabapentin among nonmedical prescription opioid users in Appalachian Kentucky.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid; | 2015 |
Abuse of Gabapentin is Associated with Opioid Addiction.
Topics: Adult; Amines; Attention Deficit Disorder with Hyperactivity; Comorbidity; Criminals; Cyclohexanecar | 2016 |
A Decade of Gabapentinoid Misuse: An Analysis of the European Medicines Agency's 'Suspected Adverse Drug Reactions' Database.
Topics: Adult; Amines; Analgesics, Opioid; Behavior, Addictive; Cyclohexanecarboxylic Acids; Databases, Fact | 2016 |
Misuse of gabapentin and pregabalin: a marker for a more serious malaise?
Topics: Biomarkers; Gabapentin; Pregabalin; Substance-Related Disorders | 2016 |
Challenges of fragmented care in long-term management of pelvic pain.
Topics: Acetaminophen; Adult; Amines; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Anxiety Agents; Chr | 2007 |
[Gabapentin abuse].
Topics: Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric | 2010 |
Gabapentin-induced delirium and dependence.
Topics: Adult; Amines; Analgesics, Non-Narcotic; Cyclohexanecarboxylic Acids; Delirium; Gabapentin; gamma-Am | 2009 |
Gabapentin blocks methamphetamine-induced sensitization and conditioned place preference via inhibition of α₂/δ-1 subunits of the voltage-gated calcium channels.
Topics: Amines; Animals; Blotting, Western; Brain; Calcium Channels; Central Nervous System Stimulants; Cond | 2011 |
Is there a recreational misuse potential for pregabalin? Analysis of anecdotal online reports in comparison with related gabapentin and clonazepam data.
Topics: Amines; Anticonvulsants; Clonazepam; Cross-Sectional Studies; Cyclohexanecarboxylic Acids; Dose-Resp | 2011 |
Gabapentin and pregabalin: abuse and addiction.
Topics: Amines; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Pregabalin; Substa | 2012 |
Gabapentin for the treatment of ethanol withdrawal.
Topics: Acetates; Adult; Alcohol Withdrawal Seizures; Amines; Anticonvulsants; Benzodiazepines; Central Nerv | 2003 |
Abuse, dependency and withdrawal with gabapentin: a first case report.
Topics: Aged; Alcoholism; Amines; Antimanic Agents; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-A | 2007 |
Open-label study of a proprietary treatment program targeting type A gamma-aminobutyric acid receptor dysregulation in methamphetamine dependence.
Topics: Adolescent; Adult; Aged; Amines; Cyclohexanecarboxylic Acids; Female; Flumazenil; Gabapentin; gamma- | 2007 |
A naturalistic study of the use of vigabatrin, lamotrigine and gabapentin in adults with learning disabilities.
Topics: Acetates; Adult; Aged; Amines; Anticonvulsants; Comorbidity; Cyclohexanecarboxylic Acids; Dose-Respo | 1997 |
Gabapentin abuse in a cocaine user: implications for treatment?
Topics: Acetates; Adult; Amines; Anticonvulsants; Crack Cocaine; Cyclohexanecarboxylic Acids; Female; Gabape | 1997 |
Gabapentin use in benzodiazepine dependence and detoxification.
Topics: Acetates; Alprazolam; Amines; Anti-Anxiety Agents; Cyclohexanecarboxylic Acids; Excitatory Amino Aci | 2001 |